Association between self-reported poor sleep status and ovulation rate in Chinese women with fertility intentions: a multicentre prospective cohort study protocol Authors: Nian-jun Su, Juan Huang, Haibo Li, Haiying Chen, Lijing Wang, Shihan Wang, Kali Huang, Jiaxian Wang, Ju Huang, Yang Liao, Lingling Li, Zhengfang Xiong, Haiqin Ren, Beimei Liu, Dongli Chen, Ning Ma, Lixue Yin, Cuiyu Huang, Xiqian Zhang, Fenghua Liu Published: 2026 ABSTRACT AbstractIntroductionIn China, women of childbearing age, who constitute a major demographic of online consumers and professionals in emerging industries are increasingly experiencing significant sleep disturbances. Existing studies have predominantly focused on the association between sleep disorders and polycystic ovary syndrome, often overlooking the independent impact of sleep patterns on ovulatory function in the general population of women attempting conception. Specifically, the synergistic effect of blue light exposure from electronic devices and delayed sleep onset remains underexplored, and evidence regarding the relationship between sleep duration, sleep quality and ovulation rates is insufficient. The primary objective of this study is to investigate the association between sleep habits and ovulation rates among Chinese women with fertility intentions. Second, it aims to determine the correlation between these sleep habits and factors such as screen time, night shift work and regional differences. Third, using a user-friendly sleep monitoring wristband, the study seeks to clarify the quantitative relationship between objective sleep parameters (eg, sleep onset time, sleep efficiency) and ovulation rates in this population.Methods and analysisThis is a 1.5-year multicentre prospective cohort study. Participants will be recruited from at least five reproductive medicine centres in mainland China between May 2025 and December 2026. The study will enrol women aged 20–50 years with fertility intentions. Baseline demographic information and habitual sleep patterns will be assessed through standardised questionnaires, with participants self-reporting their sleep conditions. Prepregnancy biochemical indicators and anthropometric data will be recorded. The primary outcome will be the ovulation rate, with secondary outcomes including pregnancy rate and miscarriage rate.Ethics and disseminationThis research project has been approved by the Clinical Research Ethics Committee of Guangdong Provincial Maternal and Child Health Hospital (Approval No.20250072), and has also received approval from the Primary and Specialty Nursing Committee for implementation and development. All participants will be informed verbally and in writing about the study procedures and objectives prior to signing the consent form. Data confidentiality will be ensured, and participants may withdraw their consent at any stage of the research. The findings will be presented at international conferences and published in peer-reviewed scientific journals. STRENGTHS AND LIMITATIONS OF THIS STUDY The use of a wrist-worn device for sleep monitoring will provide objective data that better reflects participants’ actual sleep patterns in their daily living environment. The use of a wrist-worn device for sleep monitoring will provide objective data that better reflects participants’ actual sleep patterns in their daily living environment. As an observational study, it will have minimal impact on participants’ routine clinical care and lifestyle. As an observational study, it will have minimal impact on participants’ routine clinical care and lifestyle. Self-reported data from patients is subject to potential recall and reporting bias. Self-reported data from patients is subject to potential recall and reporting bias. The observational design provides a lower level of evidence compared with randomised controlled trials. The observational design provides a lower level of evidence compared with randomised controlled trials. As recruitment will be limited to reproductive medicine departments, a selection bias may exist, potentially limiting the generalisability of the findings to all women with fertility intentions in China. As recruitment will be limited to reproductive medicine departments, a selection bias may exist, potentially limiting the generalisability of the findings to all women with fertility intentions in China. Introduction With the acceleration of life pace and increasing social pressures, sleep disorders have become a widespread issue affecting global health.1 Approximately 16.2% of the world’s population suffers from some degree of sleep disorder.2 In recent years, poor nighttime sleep among Chinese residents has shown a trend of becoming more prevalent, chronic and widespread. A national cross-sectional survey in 2022 found that 46.8% of the Chinese population reported experiencing insomnia symptoms.3 Although meta-analyses applying strict diagnostic criteria estimate the prevalence of poor sleep quality at 19.0%,4 the high rate of self-reported sleep complaints highlights the growing public health burden of sleep disorders in China. Poor sleep encompasses a range of conditions including insufficient sleep duration, poor sleep quality and circadian rhythm disorders. These are influenced by multiple factors such as occupation, smoking habits,5 prebedtime use of electronic devices, late-night eating6 and vary across different regions due to environmental differences.7 For Chinese women, the ‘2025 China Sleep Health Survey Report’ indicates that 51.1% experience sleep problems, characterised by reduced sleep duration, delayed sleep onset and decreased sleep quality. Over the past 5 years, China has seen the rapid growth of nighttime economy industries, such as e-commerce live streaming. As the primary participants in online consumption and the workforce in these emerging professions, women of childbearing age have experienced a significant increase in the prevalence of late-night activities,3 exacerbating sleep issues in this group. Lifestyle changes—including late nights, high-energy diets, sedentary behaviour and insufficient sunlight exposure—are recognised as key contributors to declining fertility among modern women of childbearing age. Sleep disorders, in particular, may significantly impact reproductive outcomes by disrupting ovulatory function and menstrual cyclicity. Current evidence presents varying risk assessments for these effects, with sleep disturbances identified as a potential risk factor for early miscarriage.8 Numerous studies suggest that sleep duration of less than 7 hours per night may be associated with decreased pregnancy success rates.9 A University of Southampton study of over 100 000 women revealed that night shift workers face an 80% higher risk of difficulty conceiving, while shift workers had a doubled annual pregnancy failure rate.10 Research further demonstrates that non-day shift work patterns increase the risk of menstrual cycle irregularity by 20% and raise miscarriage risk by approximately one-third.11 A Danish cohort study of 22 744 pregnant women confirmed that night shift work elevates miscarriage risk.12 These effects are hypothesised to stem from the disruption of the hypothalamic-pituitary-ovarian (HPO) axis function,13 which regulates reproductive hormones such as gonadotropin-releasing hormone, follicle-stimulating hormone (FSH) and luteinising hormone (LH), thereby affecting ovulation. Human studies have observed associations between sleep disturbances and menstrual irregularities or infertility. Furthermore, patients with polycystic ovary syndrome often experience comorbid sleep disorders,14 potentially creating a vicious cycle. These findings suggest that improving sleep quality may be a modifiable factor to support healthy ovulatory function. Current research has primarily focused on the association between sleep disorders and reproductive outcomes in the context of assisted reproductive technology, yet the impact of sleep patterns on ovulatory function in the general population attempting natural conception is less understood. In particular, the synergistic effects of blue light exposure from electronic devices and delayed sleep onset remain underexplored, with a lack of specific evidence regarding the relationship between sleep duration, sleep quality and ovulation rates. For instance, whether bedtime, sleep onset time, total sleep time and sleep quality independently influence ovulation rates remains unclear. To date, there is no consensus on the definition of optimal sleep habits for fertility. Existing research suggests that a sleep duration of 6–8 hours may be recommended.15 The gold standard for sleep assessment, polysomnography, is costly and requires an overnight stay in an unfamiliar environment,16 rendering it impractical for most large-scale clinical studies. Therefore, this study aims to address these evidence gaps by investigating the association between sleep habits and ovulation rates. Methods/design This study is a 1.5-year multicentre prospective cohort study. The research period will span from 1 May 2025 to 31 December 2026. Participants will be recruited from at least five reproductive medicine centres across mainland China between May 2025 and December 2026. The study population will consist of women aged 20–50 years (excluding those aged 50 years) with fertility intentions. The study has commenced recruitment as of the protocol submission date (figure 1). Methods. During the first follicular monitoring visit, baseline data—including sociodemographic characteristics, ovarian monitoring status, sleep conditions over the past month will be collected using a self-administered questionnaire developed via the WeChat survey platform (online supplemental document 1). This questionnaire will serve solely as a background assessment tool to collect demographic characteristics and habitual sleep patterns, and will not be used as the primary source of longitudinal sleep data. The questionnaire will be distributed electronically to participants at the time of enrolment via a quick response code printed on the study recruitment flyer or a shared link sent through the hospital’s official WeChat account. Participants will complete the questionnaire on their own smartphones prior to their first follicular monitoring visit. Prior to formal data collection, the questionnaire was pretested for face validity, content validity and feasibility among 30 women of reproductive age (aged 20–49 years) who were recruited from the outpatient clinic of Guangdong Women and Children Hospital between 1 March 2025 and 15 March 2025. These women were invited to complete the questionnaire independently and were subsequently interviewed by a research assistant to provide structured feedback on the following aspects: clarity of wording, comprehensiveness of response options, relevance of each item to their sleep habits and the time required for completion. The final version of the questionnaire was then reviewed and approved by all coauthors before being integrated into the study protocol. The final questionnaire incorporates the full, validated versions of the Pittsburgh Sleep Quality Index (PSQI) and the Patient Health Questionnaire-9 (PHQ-9) as core components, enabling comprehensive assessment of sleep quality and depressive symptoms within a single self-administered instrument. Clinicians will provide recently measured blood pressure and biochemical parameters (eg, oestrogen, progesterone, FSH, LH, homocysteine (HCY), cortisol, fasting blood glucose (FPG)). Subsequently, daily sleep efficiency will be monitored using the Xiaomi Smart Band 6 and its accompanying smartphone application (Xiaomi Sports & Health), recording bedtime, sleep onset time, nighttime sleep duration, daytime nap duration and durations of deep, light and rapid eye movement (REM) sleep. Outdoor temperature will be recorded via a smartphone weather application. Participants will document these data in a structured sleep monitoring diary (online supplemental table 1), which will serve as the primary source of sleep-related information. Researchers will periodically verify the diary entries against raw data from the application to ensure accuracy and completeness. The sleep diary will include at least three working days and one rest day per week. To minimise device-related variability, all participants will use the same model of smart bracelet (Xiaomi Smart Band 6), and temperature data will be collected uniformly via smartphone weather applications. Daily step counts will also be recorded from the bracelet and entered into the diary. All participants will undergo natural cycle monitoring. Ovulation will be determined by transvaginal ultrasound and serum progesterone levels. A dominant follicle reaching 18–25 mm in diameter will be considered mature. Ovulation will be confirmed if any of the following are observed: disappearance of the mature follicle, follicular wall collapse or presence of free fluid in the rectouterine pouch, combined with a mid-luteal serum progesterone level >16.05 nmol/L (>5 ng/mL). Pregnancy testing will be performed 14 days after confirmed ovulation, and clinical pregnancy will be confirmed by ultrasound at 12 weeks of gestation. All data will be entered centrally into an Electronic Data Capture system by trained researchers at each participating centre. Inclusion criteria Chinese women aged 20–50 years with childbearing needs. Exclusion criteria Suffering from severe insomnia, depression or anxiety, requiring long-term psychiatric medication. Suffering from severe insomnia, depression or anxiety, requiring long-term psychiatric medication. Hypertension, diabetes, thyroid dysfunction, hyperprolactinaemia not well controlled. Hypertension, diabetes, thyroid dysfunction, hyperprolactinaemia not well controlled. History of ovarian/uterine/fallopian tube malignancy. History of ovarian/uterine/fallopian tube malignancy. Uterine fibroids or ovarian cysts with an average diameter of 4 cm or more. Uterine fibroids or ovarian cysts with an average diameter of 4 cm or more. Untreated submucosal uterine fibroids or endometrial polyps. Untreated submucosal uterine fibroids or endometrial polyps. Variables Sociodemographic variables The following data will be recorded in the first interview of the ovulation monitoring cycle: age (years), ethnic group, marital status, residential place, educational level, working status, nature of labour, number of night shifts (between 11 pm and 7 am) per 30 days, work hours after 11 pm, number of rest days within the past 30 days, number of children born, whether sharing a bed with someone during nighttime sleep, whether nighttime awakenings are related to childcare, typical number of hours of sleep needed to feel well the next day, average length of menstrual cycles over the past 3 months, daily time spent using blue light devices, time interval between electronic device use and bedtime, whether you check your phone or read in bed before sleep, and whether you have chronic conditions (requires physician diagnosis); long-term medication use; smoking status; air conditioner use in the past 30 days; PSQI and PHQ-9 related questions. Anthropometrics Participants will undergo weight measurement in the morning of their initial follow-up visit (shoes removed and light clothing worn), while height measurement will be conducted during the same visit (shoes removed when standing, with the midline aligned with the measuring board). Final data will be calculated as the average of both measurements. All measurements are performed by professionally trained researchers to minimise interobserver variability. The equipment used includes a mechanical scale (maximum capacity 220 kg, precision 50 g) and a wall-mounted height metre (range 0–200 cm), both regularly calibrated by the hospital’s equipment department. Body mass index is calculated using the formula: weight (kg) divided by height squared (m). Arterial blood pressure The blood pressure will be measured twice, with a 5-minute interval between each measurement. The first measurement will be conducted after at least 5 min of rest. Female subjects will sit in a relaxed position with their right arm half-flexed at heart level. Blood pressure will be measured using the OMRON HBP-9020 monitor (Omron Inc., Dalian, China). Biochemical parameters The research data will be collected by professional researchers. All blood samples must be drawn from the right or left elbow crease between 8:00 am and 10:00 am, 8–12 hours after fasting. The tests include: FPG, fasting insulins, alanine aminotransferase, uric acid, total cholesterol, triglycerides, low-density lipoprotein cholesterol, vitamin D, HCY, stress hormones (such as cortisol), serotonin. Melatonin collection will not be conducted in this study due to its collection requiring early morning hours, rapid individual variations and practical difficulties in sample collection. Ovulation monitoring protocol Combining transvaginal ultrasound monitoring of follicular development with serum progesterone testing. Monitoring begins on days 3–5 of each participant’s natural menstrual cycle. For shorter cycles (<21 days), it may start earlier (days 2–3); for longer cycles (>35 days), it may be delayed to days 5–7. ALOKA ARTETTA 60 transvaginal ultrasound is uniformly used to measure and record the following indicators: ovaries (size of both ovaries, number of antral follicles), dominant follicle (location marked, average diameter measured and recorded), endometrium (thickness recorded (double-layer) and classification (A, B, C types)). Monitoring frequency: early follicular phase (dominant follicle diameter<14 mm): every 2–3 days. Late follicular phase (dominant follicle diameter≥14 mm): every 1–2 days until ovulation. Ovulation determination criteria: When the dominant follicle diameter reaches 18–25 mm, it indicates maturity. In subsequent monitoring, if any of the following are observed: disappearance of mature follicles, follicular wall collapse, or free fluid in the rectouterine pouch, ovulation is confirmed. Ovulation confirmation is the most critical step, occurring 5–7 days after ultrasound indicates ovulation (equivalent to mid-luteal phase). This confirmation should be combined with serum progesterone levels. Prior to ovulation, the first blood sample drawn for progesterone serves as the baseline reference. Progesterone levels should be at the low follicular phase range (typically<3.18 nmol/L or<1 ng/mL). If progesterone is already elevated at this stage, it may indicate that the follicle in this cycle has undergone luteinisation (transitioning directly to a corpus luteum without ovulation) or that other endocrine issues are present. Blood progesterone is re-drawn 5–7 days after ultrasound-confirmed ovulation, during the mid-luteal phase. Clinical significance: Serum progesterone levels>16.05 nmol/L (> 5 ng/mL) typically indicate ovulation. Optimal standard: serum progesterone levels>31.8 nmol/L (> 10 ng/mL) not only to confirm ovulation but also to indicate robust luteal function capable of fully supporting endometrial transformation and preparing for potential embryo implantation. The study cycle ends if any of the following conditions are met: (1) Ovulation confirmed: ultrasound and serum progesterone levels show ovulation signs. (2) Ovulation not confirmed: no dominant follicle development or persistent follicles without ovulation signs observed by day 25 of the cycle, or when follicle diameter exceeds 25 mm and the absence of ovulation indicates luteinised unruptured follicle syndrome, a form of anovulation. (3) Ovulation occurs only after administration of Human Chorionic Gonadotropin (HCG)-primed ovulation-inducing drugs. Physical activity Read the number of steps taken each day through the smart wristband. Variables associated with sleep habits During the initial follicular monitoring interview, the PSQI was administered via questionnaire to assess sleep quality, while the PHQ-9 evaluated anxiety levels. The PSQI, a widely used clinical tool for assessing sleep quality in adults, evaluates seven dimensions: sleep quality, sleep onset time, sleep duration, sleep efficiency, sleep disturbances, medication use and daytime functioning. Each dimension is scored from 0 to 3, with a total score ranging from 0 to 21. A score≤5 indicates good sleep quality. Scores>5 suggest sleep issues, with higher scores indicating poorer sleep quality. The PHQ-9, a self-administered depression screening tool, assesses depressive symptoms (eg, low mood, loss of interest, sleep disturbances) over the past 2 weeks. Each item is rated from 0 to 3, with a total score of 0–27. Normal scores: 0–4 indicate no or minimal depression. Abnormal scores: 5–9: mild depression; 10–14: moderate depression; 15–19: moderate to severe depression; ≥20: severe depression. The follicular monitoring programme commenced with participants maintaining daily sleep diaries. These entries included: workday status, presleep blue light device cut-off time and bedtime interval (minutes), final presleep meal timing and its interval from bedtime (minutes), actual bedtime, nighttime wake-up frequency, snoring occurrence and self-reported sleep quality. Using smart wristbands and smartphones, the system tracked and recorded the following metrics: presleep outdoor temperature, sleep onset time, wake-up time, nighttime sleep duration, deep sleep duration, light sleep duration, REM sleep duration, napping duration, total sleep duration and step count. The sleep log requires a minimum recording cycle of 4 days, including at least 3 working days and 1 rest day. All metrics for working days are calculated based on averages, with the same methodology applied to rest days. Participants must wear the smart bracelet continuously for 7 days (24 hours) on the non-dominant wrist during bathing and aquatic activities. The device will track baseline data (heart rate, blood pressure), sleep latency, total sleep duration, sleep efficiency (nighttime sleep duration/(wake-up time-bedtime)) and step counts. All participants will receive usage instructions for the smart bracelet through both verbal and written guidance. The Xiaomi Mi Band 6 is used for data collection, with all data downloaded via the Xiaomi Sports & Health app. Pregnancy outcomes A urine pregnancy test will be performed 14 days postovulation. In case of a positive result, transvaginal ultrasound will be performed 14 days later to confirm the presence and location of a gestational sac and fetal heartbeat. Clinical pregnancy will be confirmed by 12 weeks of gestation, with ongoing pregnancy followed until term. Patient and public involvement There was no patient or public involvement in the design of this protocol. Statistical analysis Participants will be categorised based on their self-reported bedtime: those who typically go to bed before 11:00 pm will be assigned to the reference group, while those who go to bed at or after 11:00 pm will be assigned to the exposure group. A power analysis for two independent proportions was performed to estimate the required sample size. Under the null hypothesis, the ovulation rate was assumed to be 0.7000 in both groups. Under the alternative hypothesis, the rate was assumed to decrease to 0.6500 in the exposure group, representing a clinically meaningful difference of 0.0500. A two-sided Z test with pooled variance was used, with a significance level of 0.0500 and a target power of 80%. The analysis indicated that a minimum of 1251 participants per group would be required. Accounting for potential non-response and data loss, the target sample size was set at 1500 participants per group.17 All statistical analyses will be performed using R software (V.3.3.2) and Free Statistics software (V.2.1). Discussion This study protocol describes the first prospective cohort study, to our knowledge, that combines objective sleep monitoring (using smartphones and a standardised smart bracelet) with rigorous, standardised ovulation verification in women with fertility intentions. This methodology aims to overcome the limitations of traditional retrospective questionnaires, which are subject to recall bias. The findings are expected to provide evidence-based insights for several key areas: informing sleep health guidelines for Chinese women with fertility intentions (eg, recommending an optimal latest bedtime), and developing targeted fertility protection strategies for high-risk groups such as night shift workers and professionals in nighttime industries. By integrating prospective sleep diaries and continuous physiological data from the Xiaomi Smart Band 6, this study will enable a nuanced exploration of the relationship between specific, quantifiable sleep parameters—such as sleep onset time, sleep efficiency and fragmentation—and ovulatory function. The detailed collection of occupational and geographic data will further facilitate analyses of sleep pattern variations across different subgroups and their differential impact on ovulation rates. The ultimate goal is to empower women with personalised, evidence-based guidance to optimise their sleep habits, thereby supporting their reproductive health and fertility goals. Previous studies relying on the PSQI to assess sleep patterns over the preceding month were subject to retrospective recall bias. In contrast, this study adopts a prospective design, initiating data collection with follicular monitoring and maintaining contemporaneous sleep diaries. This approach will provide a more accurate and temporally relevant assessment of the sleep exposures preceding each ovulatory cycle. This study has several limitations that should be acknowledged. As a prospective cohort study, it provides a lower level of evidence compared with randomised controlled trials and cannot establish causality. The decision not to collect melatonin, due to the practical challenges of its diurnal variation and requirement for serial overnight sampling, means we cannot explore its potential mediating role in the sleep-ovulation pathway. Furthermore, recruiting participants exclusively from reproductive medicine clinics introduces a potential selection bias, as this population may have different baseline characteristics (eg, higher prevalence of subfertility) compared with the general population of women with fertility intentions. This may limit the generalisability of our findings. We acknowledge this limitation and will discuss its implications for interpreting the results. Further research will be needed to elucidate the differential effects of sleep deprivation on fertility across specific age groups, particularly among women aged 35 years and older. Future studies could also expand recruitment to community-based settings to enhance generalisability and explore the molecular mechanisms underlying the hormonal regulation of the HPO axis by sleep. Investigating the therapeutic potential of interventions such as melatonin supplementation or light therapy for reversing sleep deprivation-related fertility impairment would also be a valuable next step. Ethics and dissemination This research project has been approved by the Clinical Research Ethics Committee of Guangdong Provincial Maternal and Child Health Hospital (Approval No.20250072), and has also received approval from the Primary and Specialty Nursing Committee for implementation and development. All participants will be informed verbally and in writing about the study procedures and objectives prior to signing the consent form. Data confidentiality will be ensured, and participants may withdraw their consent at any stage of the research. The findings will be presented at international conferences and published in peer-reviewed scientific journals. Supplementary material